Coronary computed tomography angiography (CCTA) is a well-validated and noninvasive imaging modality for the assessment of coronary artery disease (CAD) in patients with stable ischemic heart disease and acute coronary syndromes (ACSs). CCTA not only delineates the anatomy of the heart and coronary arteries in detail, but also allows for intra-and extraluminal imaging of coronary arteries. Emerging technologies have promoted new CCTA applications, resulting in a comprehensive assessment of coronary plaques and their clinical significance. The application of computational fluid dynamics to CCTA resulted in a robust tool for noninvasive assessment of coronary blood flow hemodynamics and determination of hemodynamically significant stenosis. Detailed evaluation of plaque morphology and identification of high-risk plaque features by CCTA have been confirmed as predictors of future outcomes, identifying patients at risk for ACSs. With quantitative coronary plaque assessment, the progression of the CAD or the response to therapy could be monitored by CCTA. The aim of this article is to review the future directions of emerging applications in CCTA, such as computed tomography (CT)-fractional flow reserve, imaging of vulnerable plaque features, and quantitative plaque imaging. We will also briefly discuss novel methods appearing in the coronary imaging scenario, such as machine learning, radiomics, and spectral CT.
INTRODUCTION
After many years of diligent scientific testing and validation, coronary computed tomography angiography (CCTA) has become an established method for assessing coronary artery disease (CAD) in patients with suspected stable ischemic heart disease [1] [2] [3] [4] [5] [6] and acute coronary syndrome (ACS). 7-9) Though the great legacy of earlier validation studies relies on the comparison of CCTA against reference standards, such as invasive coronary angiography (ICA), more recently, the inherent characteristics of CCTA, including 3-dimensional (3D) anatomic data and both intraluminal and extraluminal imaging, naturally allowed the emergence of newer applications in noninvasive cardiac imaging. Computational fluid dynamics (CFD) applied to CCTA have proven value in the noninvasive determination of coronary blood flow hemodynamics, 10) while plaque imaging has uncovered a multitude of imaging biomarkers capable of defining the disease stage and predicting future outcomes. Therefore, cardiac imaging research has shifted throughout the years from a luminography perspective towards a more comprehensive utilization of CCTA data. This trend has been also recently boosted by the emergence of advanced computational methods, including machine learning and artificial intelligence. 11) In this paper, we will review the growing role of CCTA in the noninvasive assessment of myocardial ischemia using computed tomography (CT)-derived fractional flow reserve (CT-FFR). We will also review the current directions in noninvasive coronary atherosclerotic plaque imaging, focusing on the research leading to the establishment of features associated with plaque vulnerability currently used in clinical practice, as well as discussing future perspectives in quantitative coronary atherosclerotic plaque assessment. Lastly, we will present examples of emerging technology and alternative imaging biomarkers that may drive future research in CCTA.
FRACTIONAL FLOW RESERVE ASSESSED BY COMPUTED TOMOGRAPHY
Fractional flow reserve (FFR) is an invasive parameter that can be obtained during coronary angiography (invasive coronary angiography-derived fractional flow reserve [ICA-FFR]) for assessing the hemodynamic significance of stenotic lesions, which is calculated as the ratio between blood flow after a stenotic lesion and the maximum normal blood flow during myocardial hyperemia. 12) Robust data from the FFR versus Angiography for Multivessel Evaluation (FAME) study showed that ICA-FFR may be a better parameter for guiding coronary revascularization than standard angiographic interpretation. The FAME study was a randomized trial involving 20 medical centers in Europe and the United States, which compared the composite endpoint including death, nonfatal myocardial infarction, and repeat vascularization of patients selected for percutaneous implantation (percutaneous coronary intervention [PCI]) of drug-eluting stents, with 2 intervention arms adjudicated either by angiography alone or by demonstration of FFR-proven ischemia (i.e., ICA-FFR ≤0.80). 13) In this study, the event rates were determined to be 18% vs. 13% (p=0.02) for the angiography vs. FFR-guided PCI strategy in the first year of follow-up, 14) respectively, and 13% vs. 8% (p=0.02) by the end of the second year. 15) A sub-analysis of the data also found that 35% of the lesions graded with 50% to 70% of stenosis by visual angiographic assessment were actually found to be hemodynamically significant on ICA-FFR, while 20% of those graded with 71% to 90% of stenosis were deemed non-hemodynamically significant on ICA-FFR. 16) In an economic analysis of the FAME study data, not only did the FFR-guided strategy for PCI lead to an increase in quality-adjusted life-years, but also to a significant decrease in healthcare costs. 17) CCTA is an established method capable of providing tridimensional (3D) anatomical visualization of the coronary arteries. Multiple prospective multicenter trials using 64-row multidetector scanner showed that CCTA has high sensitivity and specificity ranging from 85% to 99% and 64% to 90%, respectively, for detecting coronary stenosis of 50% or more determined by conventional angiography in cohorts of patients with suspected CAD. [18] [19] [20] However, it was shown that quantitative luminal assessment by CCTA and ICA have only weak correlation with ICA-FFR (r=−0.32 and r=−0.30), respectively. 21) More recently, CFD methods have been introduced in noninvasive coronary imaging, with the goal of determining the hemodynamic significance of stenotic lesions. 22) In summary, the precursor method introducing CFD for coronary hemodynamics analysis consists of 3 steps: 1) 3D modeling of the coronary tree anatomy based on standard CCTA data, 2) defining the boundary conditions for cardiac output, aortic pressure, and myocardial microvascular resistance, and 3) solving the Navier-Stokes equations for estimation of blood flow conditions within the 3D model. [23] [24] [25] In an initial study (Diagnosis of Ischemia-Causing Stenoses Obtained Via Noninvasive Fractional Flow Reserve [DISCOVER-FLOW]), FFR was estimated from CFD modeling in 158 vessels from 103 patients concurrently undergoing CCTA (CT-FFR) and ICA-FFR at 4 centers (Figures 1 and 2) . In this investigation, CT-FFR predicted a per-vessel ICA-FFR ≤0.80 with an accuracy of 84.3%, sensitivity of 87.9%, and specificity of 82.2%; in contrast, standard CCTA interpretation (i.e., stenosis ≥50% by visual analysis) had an accuracy of 58.5%, sensitivity of 91.4%, and specificity of 39.6%. The area under the receiveroperator characteristics curve (AUC) for detecting ICA-FFR ≤0.80 was significantly higher in CT-FFR when compared with standard CCTA interpretation (0.90 vs. 0.75, p=0.001). 
FFRCT .
FFR . CAD as determined by ICA-FFR (AUC of 0.81 vs. 0.68, respectively, p<0.001). 26) In another multicenter study (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps [NXT]), including 254 patients with suspected stable CAD, CT-FFR showed specificity of 79% to diagnose significant ischemia on a per-patient basis, which was significantly superior to CCTA (34%, p<0.001) and statistically similar to standard quantitative analysis of ICA (83%, p=0.29). 27) This study also revealed good correlation between CT-FFR and invasive ICA-FFR (Pearson's R=0.82; p<0.001), with slight underestimation of ICA-FFR by CT (difference of 0.03±0.07, mean±standard deviation). 27) Determination of CT-FFR using the aforementioned technique requires intensive post processing using parallel supercomputing capabilities from a remote core lab service, 10)26)27) which has become approved for clinical use in several countries. More recently, on-site approaches for CT-FFR analysis using modified algorithms have also emerged. 28-32) 
Computed tomography-derived fractional flow reserve versus myocardial perfusion
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FFR . intention-to-diagnose analysis, PET outperformed CT-FFR on a per-patient basis (AUC 0.90 vs. 0.79; p=0.005, respectively), but not on a per-vessel basis (AUC 0.86 vs. 0.83; p=0.157, respectively). In another prospective head-to-head comparison in 147 symptomatic patients referred for ICA-FFR (PERfusion Versus Fractional Flow Reserve CT Derived In Suspected CoroNary; PERFECTION study), "resting" CCTA with CT-FFR and "stress" computed tomography perfusion (CTP) were directly compared. Both CT-FFR and CTP outperformed CCTA alone on a per-vessel (accuracies of 92% and 94% vs. 82%, both p<0.001, respectively) and on a per-patient basis (accuracies of 87% and 92% vs. 73%, p= 0.001 and p<0.001, respectively), while there were no statistically significant differences between CT-FFR and CTP. Another more recent study including a smaller sample of 85 patients referred for ICA-FFR scanned in a whole-heart coverage CT scanner revealed that the combination of CCTA, CT-FFR, and CTP may outperform either one of the individual methods (AUC 0.92; p<0.05), while maintaining reasonable radiation dose (average effective dose of approximately 8 mSv for the combination of CCTA and CTP). 33) A smaller study including 37 patients undergoing perfusion cardiac magnetic resonance perfusion (CMR-P) and CT-FFR also showed correlation between ICA-FFR and a CMR-P for areas of myocardium distal to stenoses between 40% and 70% (r=−0.63; p<0.001), which was comparable to the correlation found between ICA-FFR and CT-FFR (r=0.675; p<0.001).
Computed tomography-derived fractional flow reserve versus clinical outcomes
Some studies have explored how CT-FFR may hold promise to improve clinical outcomes. The "Prospective Longitudinal Trial of FFRCT: Outcome and Resource iMpacts" (PLATFORM) study was a randomized trial including 584 patients from 11 centers, where the investigators tested the outcomes of employing CCTA with CT-FFR compared with standard non-invasive testing (i.e., any form of stress testing or CCTA without CT-FFR) in patients with new onset chest pain. They found that CT-FFR could reduce the number of diagnostic ICA with non-obstructive disease from 73% to 12% (p<0.001) at comparable cumulative radiation doses, 34) while reducing resource utilization/costs and improving quality of life. 35) Using "realworld" data from the ADVANCE registry, which included 5,083 patients, investigators have recently shown that CT-FFR may modify patient management in up to 70% of the cases (95% confidence interval [CI], 65-78%) when compared to CCTA alone. 36)
PLAQUE VULNERABILITY
One of the intrinsic technical advantages of CCTA over ICA is allowing direct atherosclerotic plaque assessment without the need for invasive transcatheter methods such as intravascular ultrasound (IVUS) or optical coherence tomography (OCT) (Figure 3) . In fact, coronary angiography can significantly underestimate atherosclerotic plaque burden, as compensatory mechanisms are known to conserve relatively stable luminal areas even when atherosclerotic plaques involve up to 40% of the total cross-section area of the vessel, known as the positive remodeling (PR) phenomenon (Figure 4) . 37) Vulnerable plaques are defined as those at risk for thrombosis secondary to rupture or erosion. 38) Although the degree of stenosis increases the risk for plaque instability, the majority of the culprit lesions found in ACSs are deemed to be nonobstructive prior to rupture. 39) Plaque characterization is an evolving field in cardiac CTA, built upon extensive knowledge derived from histopathologic studies. 40 mean areas across proximal and distal reference sites (i.e., remodeling index). They observed an increase in the remodeling index in culprit plaques in ACS patients when compared with stable plaques in ACS and SA patients (respective remodeling indexes of 1.4±0.4 vs. 1.0±0.4 vs. 1.2±0.3, p=0.04, mean±standard deviation).
In addition to PR, the histopathologic study of coronary arteries has also shown common characteristics in ruptured plaques, such as large necrotic cores and a thin fibrous caps. 40) For instance, in a histopathologic study designed to understand targetable biomarkers of vulnerable atherosclerotic plaques for invasive and noninvasive imaging, Narula et al. 42) analyzed 295 coronary lesions including stable, vulnerable, and disrupted plaques. Atherosclerotic fibrous cap thickness was determined to be the best discriminatory feature for identifying the vulnerable plaques. On CCTA, the "napkin ring" has been proposed as a noninvasive way of assessing for thin-cap fibroatheromas with CCTA. 43) This sign consists of a low-attenuation plaque core surrounded by a thin hyperattenuating ring (Figure 5) . Although the histopathologic substrate of the napkin ring sign is still debatable, its genesis is attributed to the contrasting CT numbers between the fibrous capsular component of the plaque and its necrotic central core. 44) In a longitudinal study including 895 patients, the hazard ratio (HR) for future ACS was 5.55 (95% CI, 2.1-14.7; p<0.001) in patients with plaques displaying the napkin ring sign, which was an independent predictor even when compared with other highrisk plaque features. 45) However, given the small magnitude of linear measurements involved in fibrous cap thickness assessment (e.g., 54-84 µm), which are significantly below the nominal spatial resolution of the current generation of clinical CT scanners, direct imaging is theoretically limited to the realm of high-resolution methods, such as transcatheter OCT. 46) In a subanalysis of Narula and collaborators' histopathologic study 42) excluding fibrous cap thickness, macrophage infiltration and necrotic core size were identified as the most important biomarkers for plaque rupture. While macrophage infiltration and plaque inflammation have become natural targets for 18F-fluorodeoxyglucose ([ 18 F]FDG) PET 47-50) and epicardial fat imaging, 51) necrotic core has been considered a natural target for CCTA assessment. Data from CCTA using submillimeter slice thickness compared with IVUS have shown that values less than 30 Hounsfield units (HU) could be used to differentiate the coronary plaques with a "soft" lipid rich core from those with a fibrous core (Figure 6) . 52) 191 https://e-kcj.org https://doi.org/10.4070/kcj.2019.0315 In a subsequent study, Motoyama et al. 53) investigated the prevalence several CCTA plaque features encountered in patients presenting with ACS and SA. They focused on features including PR, defined as a 10% increment in diameter at the plaque region when compared to a normal reference segment, and plaque consistency. The latter is subdivided based on the presence of calcifications (attenuation >220 HU) and their size (<3 mm in size defined as "spotty" vs. "large"). Noncalcified plaques were further subdivided into those with core attenuation <30 HU ("low-attenuation" core [LAC]) or between 30 HU and 150 HU. They found that PR, LAC, and spotty calcification were significantly more prevalent in ACS than SA (87% vs. 12%, p<0.001; 79% vs. 9%, p<0.001; and 63% vs. 21%, p=0.0005, respectively). In contrast, large calcifications were found more frequently in SA than ACS (55% vs. 22%, p=0.004). 53) Other studies have further confirmed the value of these high-risk plaque features for determining future ACS. In a longitudinal study including 1,059 patients imaged with CCTA, Motoyama et al. 54) found that PR or LAC (alone or in combination) were independent predictors of future ACS within a 12-50 months follow-up, with a HR of 22.8 (95% CI, 6.9-75.2; p<0.001) when compared with patients displaying neither one of these features on CCTA; these findings were subsequently confirmed by the same group in a larger cohort of 3,158 patients followed for 3.9±2.4 years. 55) In the CCTA arm of Rule Out Myocardial Ischemia/Infarction by Computer Assisted Tomography (ROMICAT) II trial, 7) high-risk features were also predictors of ACS in patients presenting to the emergency department with acute chest pain, independent of presence of obstructive CAD and clinical risk assessment. 56) More recent analyses of large longitudinal multicenter trials have also confirmed the role of high-risk plaque features in predicting adverse major cardiovascular events. In a sub-analysis of the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial, 5) investigators studied if CCTA features of high-risk plaque ("vulnerable") and significant stenosis could predict a composite endpoint including death, myocardial infarction, or SA in the 4,415 patients undergoing CCTA. Vulnerable plaques were associated with higher event rates (HR, 2.73; 95% CI, 1.89-3.93), even after adjustments for ASCVD risk score and significant stenosis (HR, 1.72; 95% CI, 1.13-2.62). 57) In a post hoc analysis of the Scottish Computed Tomography of the HEART Trial (SCOT-HEART), the investigators found a HR of 3.01 (95% CI, 1.61-5.63; p=0.001) for a composite endpoint of coronary heart disease death or nonfatal myocardial infarction in patients with at least one adverse plaque feature when compared with those without any. 58) As a result of the robust evidence for high-risk plaque features available in the literature, guidelines on CCTA reporting available on the Coronary Artery Disease Reporting & Data System (CAD-RADS™) have included a descriptor for vulnerability ("V" modifier), which is based on the presence of at least 2 of the following findings: PR, low attenuation, spotty calcification, or napkin ring. 59) In a study determining the inter-observer agreement of CAD-RADS™ lexicon including 50 CCTA with 8% prevalence of high-risk plaque features ("V"), Fleiss' Kappa for spotty calcification, napkin ring sign, PR, and low attenuation plaque were 0.29 (p<0.001), 0.15 (p=0.013), 0.34 (p<0.001), and 0.24 (p<0.001). 60) As a future perspective, more objective assessment methods could be developed to improve the slight to fair inter-observer agreement currently observed.
Future Directions in Coronary CT Angiography
QUANTITATIVE PLAQUE ASSESSMENT
More recently, efforts have been made to extract quantifiable and reproducible features from digital medical imaging, known as quantitative imaging biomarkers. 61) These features can be used to diagnose disease, determine severity, and monitor progression or response to therapy. Coronary calcium scoring using the Agatston method is the precursor quantitative imaging biomarker in cardiac CT. 62) Nowadays, technological advances have recently allowed semi-automatically our automatically imaging analysis, decreasing post processing times and improving inter-observer variability. 63) These quantitative tools for coronary plaque assessment on CCTA that emerged in the last decade 64)65) have the potential to leverage the clinical utilization of coronary atherosclerotic plaque quantitative imaging biomarkers. Quantitative biomarkers in coronary imaging have been explored in different scenarios, such as for predicting significant hemodynamic stenosis, future plaque rupture, and monitoring disease progression or response. For instance, preliminary feasibility data comparing a quantitative CCTA (QCCTA) software with quantitative conventional ICA analysis revealed good correlations between CCTA and ICA determined stenosis (per-vessel R=0.83, p<0.01; per-patient R=0.86, p<0.01), with mean biases of −3.0±12.3% (per-vessel) and −6.2±12.4% (per-patient). 64) This study also showed improved accuracy for diagnosing lesions with stenosis ≥50% on QCCTA (95%) vs. visual CCTA analysis (87%, p=0.08). In a post hoc analysis of the NXT trial, 27) the investigators used a semi-quantitative approach to extract multiple QCCTA parameters from coronary plaques in patients with SA concurrently assessed with CCTA and ICA-FFR. 66) The investigators found that the volume of low-attenuation noncalcified plaque was a predictor of ICA-FFR-proven ischemia independent from the degree of coronary stenosis (Figure 7) .
QCCTA was also studied in the context of prediction of future atherosclerotic plaque rupture. In a single center longitudinal study including 1,256 with suspected CAD undergoing CCTA, the investigators determined if QCCTA plaque features could predict a composite endpoint of cardiac death, myocardial infarction, unstable angina, or coronary revascularization after 90 days of the scan. Events occurred in 3.9% of the patients over a median follow-up interval of 5.7 years. The investigators found that low-attenuation plaque volume and total noncalcified plaque volume could predict future events after adjustment for extension of CAD, with HRs of 1.06 (95% CI, 1.01-1.1; p=0.018) and 1.10 (95% CI, 1.01-1.2, p=0.026), respectively; however, in the multivariate model, low-attenuation plaque volume was the only parameter showing incremental predictive value to coronary Agatston score, segment stenosis score, and clinical risk score. 67) In another single center case-control study including 2,748 patients, the investigators found that multiple QCCTA parameters, including volumetry of different plaque components (noncalcified, low-attenuation noncalcified, calcified, total) and quantitative stenosis, were significantly associated with cardiac mortality (p<0.025). 68) A sub-analysis of the ROMICAT II CCTA trial arm 7) has also confirmed the ability of QCCTA to identify culprit plaques in ACS using optimized CCTA-based threshold values. 69) More recently, QCCTA has shown promise to become an objective tool for disease staging. Much information about the role of QCCTA in the assessment of the natural history of CAD has been generated from longitudinal trials or registries looking at patients undergoing serial CCTAs over long time intervals. 70) In the Progression of Atherosclerotic Plaque Determined by Computed Tomographic Angiography Imaging (PARADIGM) registry, changes in QCCTA biomarkers were used as surrogate indicators for coronary plaque progression. In this study, the investigators were able to confirm the role of diabetes mellitus as a significant risk factor for atherogenesis, especially of adverse plaque features. In another longitudinal multicenter trial including 147 patients sequentially imaged with CCTA, the investigators addressed serial changes in coronary plaque burden over a minimum interval of 24 months, with focus on determining the effects of intensive therapeutic regimens to lower low-density lipoprotein cholesterol (LDL-C). 71) Overall, multiple QCCTA parameters, such as plaque volume, mean plaque burden, maximal plaque thickness, and amount of dense calcium, have significantly increased over the follow-up interval, but interestingly, the sub-analysis of patients with LDL-C <70 mg/dL revealed a significantly smaller increase in plaque volume when compared with those with LDL-C ≥70 mg/dL.
TECHNOLOGY INNOVATIONS AND EMERGING IMAGING BIOMARKERS
So far, we have explored the data behind the mainstream directions of CCTA. However, it is worthwhile to briefly mention some of the technological innovations in image acquisition, post processing, and other imaging biomarkers that have recently grown in importance, and that will likely impact how CCTAs are performed, interpreted, and clinically used in the near future.
Spectral/dual-energy CT has emerged as a new technology over a decade ago, and has become a versatile problem solver in different scenarios. 72) Some of the clinical applications involving spectral/dual-energy CT in cardiovascular imaging include amplification of intravascular contrast agent signal/attenuation, allowing for improved contrast to noise ratio in angiographic studies, 73) reduction of metallic, beam hardening and calcium blooming artifacts, 74) detection of myocardial perfusion or scarring using iodine density mapping, and characterization of atherosclerotic plaque. 75) More recently, photon-counting detector (PCD) scanners have surged as the newer iteration of spectral CT technology, with the promise to not only enhance the multi-energy/multi-material decomposition applications in CT, but also to provide high-resolution imaging of the coronaries. A preliminary study using a prototype version of a clinical PCD-CT scanner for coronary artery calcium scoring showed that the calcium to soft tissue contrast and contrast-to-noise ratios were significantly improved in PCD-CT when directly compared conventional CT images (i.e., obtained with energy integrating detectors) (p<0.01); in addition to better image quality, PCD-CT also performed better at lower energy levels when compared to conventional CT. 76) Another study using the same prototype demonstrated the clinical feasibility of high-resolution coronary imaging (0.25-mm-thick slices) using PCD-CT. The investigators found that stent imaging could be significantly improved by using the high-resolution PCD-CT acquisition when compared to standard dual-energy technique. 77) Future studies are still necessary to test if high-resolution imaging with PCD-CT could result in significant improvements in plaque characterization and quantification.
The future seems to be also prosperous for post processing techniques that incorporate recent developments in machine learning and artificial intelligence. As previously mentioned, although CFD-based CT-FFR has been already been established in clinical practice, newer evidence has also shown the potential for use of CFD in wall-shear stress imaging, 78) which may be a predictive element in plaque rupture. 79)80) Adverse hemodynamic plaque characteristics assessed with CFD appear to increase the capabilities of CCTA to identify culprit plaques causing ACS. 81) Even simpler methods looking at the coronary arterial geometry and tortuosity were also explored as potential biomarkers for understanding coronary atherogenesis. 82) Radiomics is a new field in medical imaging, based on the extraction of hundreds of quantitative engineered features from digital images, more extensively studied in oncologic patients, but recently proposed as an investigative tool in cardiac imaging research. 83) For example, radiomics features have recently shown promise to identify characteristics of vulnerability in coronary plaques with superiority in comparison to conventional methods. 84) 85) Machine learning encompasses a wide range of computer-based algorithms that make predictions based on massive amounts of learning data. 11) Differently from classic statistical methods, machine learning algorithms are dynamic and iterative, with predictions that are expected to improve with incremental learning data. For example, Dey et al. 86) investigated the diagnostic performance of a machine learning boosted ensemble algorithm built on top of QCCTA features from atherosclerotic plaques in 254 patients undergoing CCTA and ICA-FFR. They found that the obtained machine learning-based risk score performed with the largest AUC for detecting FFR-proven ischemia when compared to degree of stenosis, lowattenuation noncalcified plaque volume, total plaque volume, and clinical assessment (AUC of 0.84 vs. 0.76, 0.77, 0.74, 0.63, p<0.006, respectively).
Lastly, we should mention the discovery of secondary imaging biomarkers available on CCTA that could serve as risk factors in genesis of atherogenesis. For example, the observation of differences in epicardial fat volume and density between patients with and without established coronary atherosclerosis have suggested a potential role for epicardial fat in the genesis of the disease. 87) Epicardial fat volume obtained from calcium scoring CT was shown to improve the predictive value for obstructive CAD over traditional coronary Agatston scoring and clinical risk factors in a large observational study. 88) Perivascular epicardial fat densification has been proposed as a surrogate for inflammatory changes, and also showed incremental predictive value to standard CCTA interpretation for identifying patients at risk for cardiac death (HR, 2.06; 95% CI, 1.50-2.83; p<0.001). 51) There is also evidence in ACS patients that perivascular epicardial fat stranding could be an ancillary predictor of the culprit lesion. 89) 
CONCLUSION
A large amount of scientific data now supports the clinical use of CCTA in the diagnosis of obstructive CAD. Current research has been shifting towards the investigation of the CCTA role in guiding patient management, identifying early predictors of ACS, and monitoring CAD progression or response to therapy. Newer methods, such as CT-FFR, have been recently translated into clinical practice, and hold the promise to provide a more specific way to determine which patients should undergo ICA. Concurrently, guidelines on structured CCTA reporting (CAD-RADS™) have already incorporated specific lexicon about plaque vulnerability. Future studies are still necessary to determine the clinical utility of quantitative plaque analysis and other quantitative imaging biomarkers, such as epicardial fat density and volume. Emerging technologies and analytical techniques such as photon-counting/ spectral CT, machine learning, and radiomics will likely provide a fruitful platform for future developments in coronary imaging.
